Reuters logo
BRIEF-Calithera Biosciences reports CB-839 Phase I triple negative breast cancer combination data
December 6, 2016 / 2:32 PM / in a year

BRIEF-Calithera Biosciences reports CB-839 Phase I triple negative breast cancer combination data

Dec 6 (Reuters) - Calithera Biosciences Inc

* Press release - Calithera Biosciences reports CB-839 Phase I triple negative breast cancer combination data at the 2016 San Antonio breast cancer symposium

* Calithera Biosciences - data show clinical activity, tolerability and unique mechanism of action of CB-839 in patients with advanced/metastatic TNBC

* Calithera Biosciences - combination of CB-839, paclitaxel has been well tolerated to date, with adverse events being easily manageable and reversible Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below